1. Right-First-Time Innovation Approach Drives Continual Investment

    Adam Kujath, Site Director at Alcami discusses implementing a right-first-time approach for optimum results.

  2. Charles River Expands CRISPR Offerings with Second License

    Company can now support customers with CRISPR/Cas9 technology from the Broad Institute and ERS Genomics.

  3. Mitigating Shortages of Injectable Drugs in the United States

    Marga Viñes, Business Development Manager at Grifols explains how to tackle drug shortages.

  4. Fucoidans Found in Seaweed Exhibit Promising Anticancer Properties

    Tumor growth rates for certain cancers were reduced in different animal models.

  5. Novo Nordisk Bags FDA Approval for New Diabetes Treatment

    Ozempic will compete with Trulicity (Eli Lilly & Co.) and Bydureo (AstraZeneca).

  6. New FDA Draft Guidance Intended to Accelerate Development of Drugs for Rare Pediatric Diseases

    Fewer patients may be needed for some clinical trials, and other trials may be eliminated.

  7. No Clinically Meaningful Difference: The Upward Trend of Biosimilars

    Following a string of approvals, biosimilars are positioned to go the way of generics.

  8. Looking forward, what technologies do you anticipate having the greatest impact in 2018?

    Experts weigh in on our Roundtable question.

  9. Moving Beyond Monoclonal Antibodies
    Next-generation antibody therapeutics are designed to provide improved specificity, efficacy and safety when compared to conventional monoclonal antibodies.
  10. Pharma’s Automation Index on the Rise
    Call it the automation of everything — a hands-off approach will permeate supply chains in the near future.
  11. Segregation in the Design of Gene Therapy Manufacturing Facilities
    Peter Walters, Lead Process Engineer for CRB USA explains segregating manufacturing operations.
  12. Phase III Study Confirms AbbVie Leukemia Combo Meets Endpoint

    Open-label, randomized study demonstrates VENCLEXTA™/VENCLYXTO™ safety and efficacy.

  13. Flexible Partnership, Inflexible Quality
    Driven by the demand for biologics, most of which still require parenteral administration, the sterile injectable market is projected to continue its 6% annual growth through 2020.
  14. Aprecia and Cycle Team to Develop 3D-Printed Orphan Drugs

    Proprietary ZipDose technology creates patient-friendly rapidly disintegrating oral forms.

  15. First “Follow-On” Insulin Product Approved

    FDA green lights Admelog to treat both type 1 and 2 diabetes.

  16. Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics

    Doug Krafte, Ph.D., Chief Scientific Officer, Neil Castle, Ph.D.
    Vice President of Research and Aaron Gerlach, Ph.D., Director of Business Development at Icagen explain the challenges and advances in the application of targeted potassium channel openers.

  17. New Generic for Kenalog-40 Approved

    Amneal launches only alternative to triamcinolone acetonide injectable.

  18. G-CON on the Road to BIO: Managing Mobility, Flexibility & Risk With Modular Design
    Michael Katsis, Director of Business Development and Sidney Backstrom, Executive Director of Business Management at G-CON Manufacturing, Inc.discuss how they provide more of a turnkey solution for customers. 
  19. Acoustics for Separation and Filtration of Applications

    Stanley Kowalski III, Co-Founder, Chairman & CEO of FloDesign Sonics discusses innovative technology for cell separation.

  20. Creating A Unique Cleanroom, Faster
    Jason Dollarhide, President of Cleanroom Constructors Incorporated explains helping clients become more FDA compliant.
Nice Insight Research
Annual Study
A study of 163 CDMOs for use by both buyers and sellers of contract services with customer ratings
702 Respondents
313 Profiles
163 Deepdive
View Directory
Annual Study
Compare ratings for 73 CROs and clinical services providers to match buyer or seller needs
609 Respondents
124 Profiles
73 Deepdive
View Directory
Annual Study
Learn customer needs directly from 541 respondents to ensure you meet them and gain sales
541 Respondents
39 Profiles
31 Deepdive
View Directory
Annual Study
Find out the most important factors in equipment purchasing from 597 customers for the year for (bio)processing
597 Respondents
137 Profiles
90 Deepdive
View Directory
Clinical Supply
Chain Annual Study
320 customers rate key factors in supporting an emerging global clinical supply chain model
320 Respondents
22 Profiles
22 Deepdive
View Directory
Annual Study
545 buyers reveal key factors in sourcing and purchasing pharmaceutical intermediates
545 Respondents
86 Profiles
62 Deepdive
View Directory
Pharma's Almanac TV
View All Video

Road To BIO: Coming Soon To Your Screen

That’s Nice is producing a film based on the Road To BIO, for release in 2017. Watch the teaser trailer to get a taster of all the behind-the-scenes stories, character insights, and what went into the project.

Facility Expansion at Abzena

John Manzello, President, US, Abzena

Attracting Investors and Shortening Development Times

James C. Greenwood, President & CEO, Biotechnology Innovation Organization (BIO)

Providing a Complete Modular Solution

George Wiker, Executive Director, AES

Bringing Bioscience to Space

Bill Goodman, Ph.D., Vice President, SCORPIO-V, a Division of HNu Photonics
Devin Ridgley, Project Scientist, SCORPIO-V, a Division of HNu Photonics

Drug Development

Fucoidans Found in Seaweed Exhibit Promising Anticancer Properties

Dec 15, 2017 11:44:03 AM PAO-M12-17-NI-025
Clinical Trials

Novo Nordisk Bags FDA Approval for New Diabetes Treatment

Dec 15, 2017 11:40:38 AM PAO-M12-17-NI-024

Charles River Expands CRISPR Offerings with Second License

Dec 15, 2017 11:30:34 AM PAO-M12-17-NI-022

Phase III Study Confirms AbbVie Leukemia Combo Meets Endpoint

Dec 14, 2017 12:37:45 PM PAO-M12-17-NI-021
Drug Development

New Generic for Kenalog-40 Approved

Dec 14, 2017 12:20:05 PM PAO-M12-17-NI-020

First “Follow-On” Insulin Product Approved

Dec 14, 2017 12:12:09 PM PAO-M12-17-NI-019
3D Printing

Aprecia and Cycle Team to Develop 3D-Printed Orphan Drugs

Dec 14, 2017 12:04:09 PM PAO-M12-17-NI-018

Results of New Gene Therapy Revealed at Hemophilia Meeting

Dec 12, 2017 1:27:27 PM PAO-M12-17-NI-017
Drug Development

ZUMA-1 Study of Yescarta Reports 58% Complete Remission

Dec 12, 2017 1:24:23 PM PAO-M12-17-NI-016

Phase II Results Reveal High-Performance Immunotherapy

Dec 12, 2017 1:21:40 PM PAO-M12-17-NI-015

Emerging Lyme Disease Tests Found Efficacious

Dec 12, 2017 1:06:56 PM PAO-M12-17-NI-014

Men in the UK Will Be Able to Buy Viagra Over the Counter Next May

Dec 8, 2017 10:36:14 AM PAO-M12-17-NI-013

Vetter Begins Construction of Packaging Facility Expansion

Dec 8, 2017 10:20:38 AM PAO-M12-17-NI-011

Genentech and Biothera to Assess Combination Cancer Therapy

Dec 8, 2017 10:17:37 AM PAO-M12-17-NI-010

University of Michigan Innovates with Kevlar Cartilage

Dec 7, 2017 3:30:14 PM PAO-M12-17-NI-009
Drug Development

U.S. Patient Receives Kite’s Yescarta CART-T Therapy

Dec 7, 2017 3:23:37 PM PAO-M12-17-NI-008

First Biosimilar to Treat Breast and Stomach Cancers Approved

Dec 7, 2017 3:13:06 PM PAO-M12-17-NI-007
Medical Application

FDA Clears KardiaBand Apple Watch Heart Monitoring App

Dec 7, 2017 2:57:55 PM PAO-M12-17-NI-006
Mergers & Acquistions

Five Critical Considerations for Pharmaceutical M&A

Dec 7, 2017 1:11:25 PM PAO-M12-17-Cl-001
Strategic Partnership

AstraZeneca Launches Strategic Joint Venture in China

Dec 5, 2017 2:36:34 PM PAO-M12-17-NI-005
Clinical Trial

Zika Vaccine Candidate Enters Phase I Trial

Dec 5, 2017 2:35:41 PM PAO-M12-17-NI-008
Strategic Partnership

Russia’s BIOCAD to Manufacture Biosimilars in North Africa

Dec 5, 2017 2:23:38 PM PAO-M12-17-NI-007
Cell and Gene Therapy

Brammer Bio Completes Renovations at Manufacturing Site in Massachusetts

Dec 5, 2017 1:59:20 PM PAO-M12-17-NI-006
Cell and Gene Therapy

Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics


Achieving Efficient Pharmaceutical Synthesis with Process Intensification


Virtual Panel

ADCs: The Future of Biologic Drugs
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game. We spoke to some of the players to find out all about ADCs.


Innovative Technologies

Design Logic

Marken: Stronger Than Ever
Now stronger than ever, Marken needed a bold visual direction to illustrate its expanding breadth of services and ongoing commitment to personalized medicine.
//Fix for text overflow in cards